Pablo
Pelegrin Vivancos
Catedraticos de Universidad
Universidad Católica San Antonio
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Universidad Católica San Antonio (6)
2023
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Zenodo
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Cell Reports Medicine, Vol. 4, Núm. 12
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Zenodo
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy
Zenodo
2021
2019
-
MCC950 closes the active conformation of NLRP3 to an inactive state
Nature Chemical Biology, Vol. 15, Núm. 6, pp. 560-564